An observational study in Non-alcoholic Steatohepatitis (MASH) and Non-alcoholic Fatty Liver Disease (MASLD), sponsored by Novo Nordisk A/S. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-11.
Sponsored by Novo Nordisk A/S · Observational
The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines.
This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.
2,081 studies on the registry are indexed under Liver Diseases; 389 are open to participants now.
This study's enrollment of 675 is above the median of 167 across 681 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Hepatologists and other metabolically focused healthcare providers (HCPs)
For Hepatologists:
5.a. Hepatology or 5.b. Gastroenterology or Internal Medicine with a subspecialty in Hepatology 6. In practice at least 3 years 7. Spends at least 50 percent of their time in an office/clinic setting 8. Spends at least 60 percent of their time in direct patient care 9. Sees at least 15 patients/month with MASH/MASLD
For Metabolically-Focused HCPs (Endocrinologist/General Physician/Family Physician/Internal Medicine):
5.a. General Physician/Family Practitioner or Endocrinology or 5.b. Internal Medicine without subspecialty in Hepatology 6. In practice at least 3 years 7. Spends less than 50 percent of their time in an office/clinic setting 8. Spends less than 60 percent of their time in direct patient care 9. Sees at least 15 patients/month with suspected/diagnosed MASH/MASLD 10. Sees and actively treats at least 30 patients/month with Type 2 Diabetes (T2D) and/or Obesity
Exclusion Criteria:
Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
Other: No treatment given
Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
Other: No treatment given
No treatment given
Unaided awareness
Open ended response
Time frame: At the time of survey response (Day 1)
Aided awareness
Multi- select from defined list
Time frame: At the time of survey response (Day 1)
Behaviours relative to diagnosing and managing MASLD
Numerical, multi-select from defined list
Time frame: At the time of survey response (Day 1)
Use of current guidelines
Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Not at all Relevant, 7=Extremely Relevant
Time frame: At the time of survey response (Day 1)
Barriers in guideline adoption
Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Doesn't impact at all, 7=Greatly impacts
Time frame: At the time of survey response (Day 1)
Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S